news
US tests international drug pricing for Medicare
The US Centers for Medicare and Medicaid Innovation (CMMI) is exploring international reference pricing for prescription drugs, aiming to bring US drug costs for Medicare Part B in line with other high-income nations. Historically, the US pays 3-5x more for the same branded drugs. This policy move is an attempt to lower the financial load on the government and, eventually, patients.
The US Centers for Medicare and Medicaid Innovation (CMMI) is exploring international reference pricing for prescription drugs, aiming to bring US drug costs for Medicare Part B in line with other high-income nations. Historically, the US pays 3-5x more for the same branded drugs. This policy move is an attempt to lower the financial load on the government and, eventually, patients.
The architecture take
The US has long been an outlier in drug pricing — the industry's ATM, really. Now CMMI is finally getting serious about benchmarking Medicare Part B drug costs to what other countries pay. This isn't just about saving government cash; it's about making essential meds more accessible, which directly impacts chronic stress and the sheer mental load of medical debt. When you can't afford the drugs you need, your nervous system takes the hit, plain and simple. Think about how many people skip doses or ration meds because of cost. It's a constant, low-level threat. Watch how pharmaceutical companies react to this — they've made a killing here for decades. I'm curious if this pressure will push more R&D into genuinely novel, rather than incremental, therapies if the profit margins on existing drugs shrink. The downstream effect could be more stable health for more people.